Galenica AG
SIX:GALE

Watchlist Manager
Galenica AG Logo
Galenica AG
SIX:GALE
Watchlist
Price: 95.95 CHF 1.53% Market Closed
Market Cap: CHf4.8B

Galenica AG
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Galenica AG
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Galenica AG
SIX:GALE
Research & Development
-CHf8.3m
CAGR 3-Years
15%
CAGR 5-Years
12%
CAGR 10-Years
N/A
No Stocks Found

Galenica AG
Glance View

Market Cap
4.8B CHF
Industry
Health Care

In the picturesque landscape of Switzerland, Galenica AG operates as a stalwart in the healthcare sector, seamlessly bridging the gap between pharmaceutical production and retail distribution. Born from a deep-rooted legacy in delivering health solutions, Galenica combines its prowess in logistics with an extensive network of pharmacies spread across the country. The magic of Galenica's operations lies in its unique dual structure. On one hand, it operates a robust logistics arm, supplying a wide array of medicines to healthcare providers, hospitals, and pharmacies. On the other hand, it runs its own retail pharmacy chains, such as Amavita and Sun Store, alongside an e-commerce platform, which make pharmaceutical care more accessible and customer-friendly for the Swiss populace. Galenica's profitability thrives on this diversified business model. By owning the supply chain from logistics to retail, the company maximizes efficiency and reduces costs, positioning itself as a leader in the Swiss pharmaceutical market. Revenue streams flow from wholesale distribution contracts, retail pharmacy sales, and a growing presence in digital health services. Furthermore, in its operations, Galenica integrates a customer-centric philosophy, leveraging data analytics to optimize stock management and personalize customer experiences—effectively enhancing earnings and customer loyalty. Through meticulous execution and strategic expansion, Galenica ensures that it remains an indispensable player in Switzerland's healthcare framework.

GALE Intrinsic Value
99.43 CHF
Undervaluation 3%
Intrinsic Value
Price

See Also

What is Galenica AG's Research & Development?
Research & Development
-8.3m CHF

Based on the financial report for Dec 31, 2025, Galenica AG's Research & Development amounts to -8.3m CHF.

What is Galenica AG's Research & Development growth rate?
Research & Development CAGR 5Y
12%

Over the last year, the Research & Development growth was 41%. The average annual Research & Development growth rates for Galenica AG have been 15% over the past three years , 12% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett